RGS20

Summary

RGS20 (regulator of G protein signaling 20, HGNC:14600) is a protein-coding gene on chromosome 8q11.23, encoding Regulator of G-protein signaling 20 (O76081). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form.

The protein encoded by this gene belongs to the family of regulator of G protein signaling (RGS) proteins, which are regulatory and structural components of G protein-coupled receptor complexes. RGS proteins inhibit signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound forms. This protein selectively binds to G(z)-alpha and G(alpha)-i2 subunits, and regulates their signaling activities. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 8601 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_003702

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14600
Approved symbol	RGS20
Name	regulator of G protein signaling 20
Location	8q11.23
Locus type	gene with protein product
Status	Approved
Aliases	RGSZ1, ZGAP1
Ensembl gene	ENSG00000147509
Ensembl biotype	protein_coding
OMIM	607193
Entrez	8601

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 4 protein_coding, 4 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000276500, ENST00000297313, ENST00000344277, ENST00000517405, ENST00000517659, ENST00000518286, ENST00000522225, ENST00000523064, ENST00000523280, ENST00000523414

RefSeq mRNA: 5 — MANE Select: NM_003702 NM_001286673, NM_001286674, NM_001286675, NM_003702, NM_170587

CCDS: CCDS6155, CCDS6156, CCDS69482

Canonical transcript exons

ENST00000276500 — 5 exons

Exon	Start	End
ENSE00002103643	53880872	53881084
ENSE00003506955	53939576	53939724
ENSE00003542199	53954076	53954310
ENSE00003559471	53958270	53959303
ENSE00003607399	53946665	53946748

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 94.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.8063 / max 80.8415, expressed in 1185 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88856	1.2764	730
88851	1.2567	625
88857	0.7043	480
88854	0.5107	308
88855	0.4967	278
88853	0.1646	68
88852	0.1553	63
88850	0.1086	47
88849	0.1071	49
88848	0.0258	5

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
caudate nucleus	UBERON:0001873	94.00	gold quality
nucleus accumbens	UBERON:0001882	93.79	gold quality
putamen	UBERON:0001874	93.40	gold quality
ventricular zone	UBERON:0003053	90.98	gold quality
amygdala	UBERON:0001876	89.81	gold quality
ganglionic eminence	UBERON:0004023	88.57	gold quality
cingulate cortex	UBERON:0003027	86.72	gold quality
anterior cingulate cortex	UBERON:0009835	86.69	gold quality
right frontal lobe	UBERON:0002810	86.67	gold quality
temporal lobe	UBERON:0001871	86.17	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.99	gold quality
telencephalon	UBERON:0001893	85.42	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.22	gold quality
lateral globus pallidus	UBERON:0002476	83.60	gold quality
Ammon’s horn	UBERON:0001954	83.07	gold quality
neocortex	UBERON:0001950	82.89	gold quality
cerebral cortex	UBERON:0000956	82.88	gold quality
prefrontal cortex	UBERON:0000451	82.77	gold quality
frontal cortex	UBERON:0001870	82.29	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.24	gold quality
middle temporal gyrus	UBERON:0002771	82.13	gold quality
forebrain	UBERON:0001890	81.61	gold quality
entorhinal cortex	UBERON:0002728	81.30	gold quality
primary visual cortex	UBERON:0002436	80.71	gold quality
brain	UBERON:0000955	79.87	gold quality
central nervous system	UBERON:0001017	79.61	gold quality
stromal cell of endometrium	CL:0002255	79.12	gold quality
superior frontal gyrus	UBERON:0002661	78.58	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.94	gold quality
postcentral gyrus	UBERON:0002581	76.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	8.45
E-ANND-3	no	4.38

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RELA, TP63

miRNA regulators (miRDB)

44 targeting RGS20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-508-5P	99.41	64.25	1248
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-4641	99.28	66.64	744
HSA-MIR-4293	99.22	65.46	1263

Literature-anchored findings (GeneRIF, showing 8)

• provide new evidence that RGSZ1 interacts not only with Galpha(z,) but also with Galpha(i), as supported by in vitro binding assays and functional studies (PMID:12379657)
• 1H, 13C and 15N resonance assignments of human RGSZ1. (PMID:14872136)
• The major function of PKCI-1 is to modulate mu opioid receptor signaling pathway along with RGSZ1, rather than directly mediating the Galphaz RGSZ1 interaction. (PMID:17126529)
• These results suggest that the expression of RGS20 may promote metastasis of tumor cells. (PMID:27495875)
• Findings suggest that high regulator of G protein signaling 20 (RGS20) expression is associated with unfavorable survival in triple-negative breast cancer (TNBC). (PMID:28237701)
• Data suggest that Gpr176 (G-protein coupled receptor 176) is an SCN-(suprachiasmatic nucleus-)enriched orphan GPCR (G-protein-coupled receptor) that sets the pace of circadian behavior; a unique cAMP-repressing G-protein subclass Gz is required for the activity of Gpr176. [REVIEW] (PMID:28502923)
• NEAT1 silencing also inhibited tumor growth in vivo. Collectively, we revealed that the NEAT1/miR365/RGS20 axis may be a novel mechanism or therapeutic strategy for OSCC treatment. (PMID:29484420)
• RGS20 acted as an oncogene in bladder cancer. (PMID:31212130)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rgs20	ENSDARG00000038859
mus_musculus	Rgs20	ENSMUSG00000002459
rattus_norvegicus	Rgs20	ENSRNOG00000008100

Paralogs (23): RGS11 (ENSG00000076344), RGS1 (ENSG00000090104), RGS17 (ENSG00000091844), AXIN1 (ENSG00000103126), RGS9 (ENSG00000108370), RGS2 (ENSG00000116741), RGS4 (ENSG00000117152), RGSL1 (ENSG00000121446), RGS13 (ENSG00000127074), RGS22 (ENSG00000132554), RGS8 (ENSG00000135824), RGS3 (ENSG00000138835), RGS5 (ENSG00000143248), RGS16 (ENSG00000143333), RGS10 (ENSG00000148908), RGS18 (ENSG00000150681), RGS12 (ENSG00000159788), AXIN2 (ENSG00000168646), RGS14 (ENSG00000169220), RGS19 (ENSG00000171700), RGS6 (ENSG00000182732), RGS7 (ENSG00000182901), RGS21 (ENSG00000253148)

Protein

Protein identifiers

Regulator of G-protein signaling 20 — O76081 (reviewed: O76081)

Alternative names: Gz-selective GTPase-activating protein, Regulator of G-protein signaling Z1, Regulator of Gz-selective protein signaling 1

All UniProt accessions (5): O76081, B3KSW4, E5RGA3, E5RH54, H9NIM5

UniProt curated annotations — full annotation on UniProt →

Function. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Binds selectively to G(z)-alpha and G(alpha)-i2 subunits, accelerates their GTPase activity and regulates their signaling activities. The G(z)-alpha activity is inhibited by the phosphorylation and palmitoylation of the G-protein. Negatively regulates mu-opioid receptor-mediated activation of the G-proteins.

Subunit / interactions. Forms a complex with G(alpha)z/i2 subunits and mu-opioid receptors; the formation of this complex results in mu-opioid receptor desensitization. Interacts with OPRM1.

Subcellular location. Membrane. Nucleus. Cytoplasm.

Tissue specificity. Isoform 5 is expressed in brain at high levels in the caudate nucleus and temporal lobe.

Post-translational modifications. Fatty acylated. Heavily palmitoylated in the cysteine string motif. N- and O-glycosylated in synapsomal membranes. Serine phosphorylated in synapsomal membranes. Sumoylated with SUMO1 and SUMO2 in synaptosomes. The sumoylated forms act as a scaffold for sequestering mu-opioid receptor-activated G(alpha) subunits.

Isoforms (6)

UniProt ID	Names	Canonical?
O76081-1	6	yes
O76081-2	1
O76081-3	2
O76081-4	3
O76081-5	4
O76081-6	5

RefSeq proteins (5): NP_001273602, NP_001273603, NP_001273604, NP_003693, NP_733466 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016137	RGS	Domain
IPR036305	RGS_sf	Homologous_superfamily
IPR044926	RGS_subdomain_2	Homologous_superfamily

Pfam: PF00615

UniProt features (11 total): splice variant 7, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O76081-F1	62.78	0.36

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-418594	G alpha (i) signalling events
R-HSA-418597	G alpha (z) signalling events

MSigDB gene sets: 144 (showing top): BENPORATH_ES_WITH_H3K27ME3, REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOCC_TRANS_GOLGI_NETWORK, ONKEN_UVEAL_MELANOMA_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, BROWNE_HCMV_INFECTION_14HR_DN, MODULE_99, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, MILI_PSEUDOPODIA_CHEMOTAXIS_UP, RICKMAN_HEAD_AND_NECK_CANCER_C, chr8q11, GOCC_CYTOPLASMIC_SIDE_OF_MEMBRANE

GO Biological Process (3): G protein-coupled receptor signaling pathway (GO:0007186), regulation of G protein-coupled receptor signaling pathway (GO:0008277), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (3): GTPase activity (GO:0003924), GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), trans-Golgi network (GO:0005802), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR downstream signalling	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
regulation of signal transduction	2
cellular anatomical structure	2
G protein-coupled receptor activity	1
G protein-coupled receptor signaling pathway	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
Golgi apparatus subcompartment	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1430 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RGS20	GNB5	O14775	878
RGS20	SUCLG2	Q96I99	853
RGS20	GNAQ	P50148	789
RGS20	ARHGEF1	Q92888	788
RGS20	ARHGEF11	O15085	785
RGS20	RGSL1	A5PLK6	771
RGS20	GRK2	P25098	769
RGS20	HINT1	P49773	751
RGS20	RGS7BP	Q6MZT1	725
RGS20	SUCLG1	P53597	721
RGS20	GNAZ	P19086	710
RGS20	GNA13	Q14344	707
RGS20	MCF2	P10911	706
RGS20	PLEK	P08567	688
RGS20	AKAP10	O43572	662

IntAct

102 interactions, top by confidence:

A	B	Type	Score
GLRX3	RGS20	psi-mi:“MI:0915”(physical association)	0.810
RGS20	GLRX3	psi-mi:“MI:0915”(physical association)	0.810
RGS20	GLRX3	psi-mi:“MI:0914”(association)	0.810
IFT43	TULP3	psi-mi:“MI:0914”(association)	0.790
RGS20	OTX1	psi-mi:“MI:0915”(physical association)	0.740
LCE1B	RGS20	psi-mi:“MI:0915”(physical association)	0.740
OTX1	RGS20	psi-mi:“MI:0915”(physical association)	0.740
RGS20	LCE1B	psi-mi:“MI:0915”(physical association)	0.740
RGS20	HOXA1	psi-mi:“MI:0915”(physical association)	0.670
CATSPER1	RGS20	psi-mi:“MI:0915”(physical association)	0.670
RGS20	CATSPER1	psi-mi:“MI:0915”(physical association)	0.670
HOXA1	RGS20	psi-mi:“MI:0915”(physical association)	0.670
HRG	PLSCR1	psi-mi:“MI:0914”(association)	0.590
RGS20	MTNR1A	psi-mi:“MI:0915”(physical association)	0.580
RGS20	MTNR1A	psi-mi:“MI:2364”(proximity)	0.580
RGS20	MTNR1A	psi-mi:“MI:0407”(direct interaction)	0.580
MTNR1A	RGS20	psi-mi:“MI:0407”(direct interaction)	0.580

BioGRID (172): RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), RGS20 (Two-hybrid), CREB5 (Two-hybrid), GLRX3 (Two-hybrid), MAPKBP1 (Two-hybrid), PVRL3 (Two-hybrid), CRCT1 (Two-hybrid), KRTAP4-2 (Two-hybrid)

ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0

Diamond homologs: A1A643, F1S668, O08773, O08774, O08849, O08850, O08899, O14921, O14924, O15169, O15492, O15539, O35625, O42400, O43566, O43665, O46469, O46470, O46471, O54828, O54829, O70239, O70240, O70521, O75916, O76081, O88566, O94810, P34295, P41220, P49758, P49795, P49796, P49797, P49798, P49799, P49800, P49802, P49803, P49804

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 43 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	6	10.1×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1735 predictions. Top by Δscore:

Variant	Effect	Δscore
8:53954062:T:A	acceptor_gain	1.0000
8:53954063:G:A	acceptor_gain	1.0000
8:53954070:A:AG	acceptor_gain	1.0000
8:53954070:AC:A	acceptor_gain	1.0000
8:53954071:C:CA	acceptor_gain	1.0000
8:53954071:C:G	acceptor_gain	1.0000
8:53954074:A:AG	acceptor_gain	1.0000
8:53954075:G:GA	acceptor_gain	1.0000
8:53954075:GCCCT:G	acceptor_gain	1.0000
8:53954233:G:GT	donor_gain	1.0000
8:53954307:GGAG:G	donor_gain	1.0000
8:53954308:GAGG:G	donor_gain	1.0000
8:53954311:GTAT:G	donor_loss	1.0000
8:53954312:T:G	donor_loss	1.0000
8:53852061:CAAG:C	donor_loss	0.9900
8:53852064:GGTAA:G	donor_loss	0.9900
8:53852065:GTA:G	donor_loss	0.9900
8:53852066:T:A	donor_loss	0.9900
8:53898856:A:T	donor_gain	0.9900
8:53939575:GCA:G	acceptor_gain	0.9900
8:53939722:GTG:G	donor_gain	0.9900
8:53946663:A:AG	acceptor_gain	0.9900
8:53946664:G:GG	acceptor_gain	0.9900
8:53954075:GC:G	acceptor_gain	0.9900
8:53954075:GCC:G	acceptor_gain	0.9900
8:53954075:GCCC:G	acceptor_gain	0.9900
8:53958265:GACA:G	acceptor_loss	0.9900
8:53958266:ACAG:A	acceptor_loss	0.9900
8:53958267:CA:C	acceptor_loss	0.9900
8:53958268:AGGTG:A	acceptor_loss	0.9900

AlphaMissense

1593 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:53954167:T:C	F279L	0.999
8:53954169:C:A	F279L	0.999
8:53954169:C:G	F279L	0.999
8:53954171:T:C	L280P	0.999
8:53954182:T:C	F284L	0.999
8:53954184:C:A	F284L	0.999
8:53954184:C:G	F284L	0.999
8:53954204:T:C	F291S	0.999
8:53954225:T:C	L298P	0.999
8:53958273:A:C	S328R	0.999
8:53958275:C:A	S328R	0.999
8:53958275:C:G	S328R	0.999
8:53958367:T:C	L359P	0.999
8:53958370:T:C	M360T	0.999
8:53958379:A:C	D363A	0.999
8:53958379:A:G	D363G	0.999
8:53958379:A:T	D363V	0.999
8:53958384:T:G	Y365D	0.999
8:53954107:T:A	W259R	0.998
8:53954107:T:C	W259R	0.998
8:53954159:T:C	F276S	0.998
8:53954168:T:C	F279S	0.998
8:53954185:A:C	S285R	0.998
8:53954187:T:A	S285R	0.998
8:53954187:T:G	S285R	0.998
8:53954196:T:A	N288K	0.998
8:53954196:T:G	N288K	0.998
8:53954203:T:C	F291L	0.998
8:53954205:C:A	F291L	0.998
8:53954205:C:G	F291L	0.998

dbSNP variants (sampled 300 via entrez): RS1000000556 (8:53873016 G>A), RS1000003414 (8:53915883 A>G), RS1000006365 (8:53853341 A>G), RS1000017943 (8:53895792 C>T), RS1000059388 (8:53921933 T>C), RS1000189413 (8:53931991 A>T), RS1000214834 (8:53897759 T>A), RS1000273034 (8:53879049 C>T), RS1000360466 (8:53928158 A>G), RS1000362856 (8:53928575 A>G), RS1000429118 (8:53877318 G>A,C), RS1000452123 (8:53934531 A>G), RS1000476541 (8:53928524 TAAA>T), RS1000494352 (8:53896088 C>T), RS1000545855 (8:53896357 G>A)

Disease associations

OMIM: gene MIM:607193 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003255_6	Urinary albumin-to-creatinine ratio	6.000000e-07
GCST005557_7	Serum uric acid levels	9.000000e-06
GCST005714_4	Cerebrospinal fluid beta-site APP cleaving enzyme levels	8.000000e-06
GCST010249_3	Chronic obstructive pulmonary disease	4.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007778	urinary albumin to creatinine ratio
EFO:0004761	uric acid measurement
EFO:0009179	beta-secretase 1 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — RZ family

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	6
Aflatoxin B1	increases expression, affects expression	4
Cadmium	increases expression, decreases reaction, increases abundance, increases palmitoylation	3
Particulate Matter	increases abundance, increases expression, affects cotreatment	3
arsenite	increases methylation, affects binding, increases reaction	2
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Tretinoin	decreases expression	2
Valproic Acid	decreases expression, decreases methylation	2
Cyclosporine	increases expression	2
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation, increases expression	2
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
cupric chloride	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
beta-hydroxy simvastatin acid	decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
(+)-JQ1 compound	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.